ClinicalTrials.gov
 Home    Search    Study Topics    Glossary  
 

  Full Text View  
  Tabular View  
  Contacts and Locations  
  Related Studies  
Design and Evaluate 12 Week Group Therapy Intervention for HIV+ Methamphetamine Users and Deliver It Within an HIV/AIDS Primary Care Setting. - 1

This study is not yet open for participant recruitment.
Verified by National Institute on Drug Abuse (NIDA), November 2005

Sponsors and Collaborators: National Institute on Drug Abuse (NIDA)
University of California, Los Angeles
Information provided by: National Institute on Drug Abuse (NIDA)
ClinicalTrials.gov Identifier: NCT00249678
  Purpose

The purpose of this study is...to assess whether placing a substance abuse intervention for HIV+ methamphetamine users within an HIV medical care setting improves rates of follow-up on referral to treatment by primary care physicians; reduces drug use and sexual risk behaviors more than treatment-as-usual; and increases rates of adherence to HIV medication regimens.


Condition Intervention Phase
Behavior Therapy
Methamphetamine
Behavioral: Behavior Therapy
Phase II

MedlinePlus related topics:   AIDS    Methamphetamine   

ChemIDplus related topics:   Methamphetamine   

U.S. FDA Resources

Study Type:   Interventional
Study Design:   Treatment
Official Title:   Behavioral Therapy Development for Methamphetamine Abuse

Further study details as provided by National Institute on Drug Abuse (NIDA):

Primary Outcome Measures:
  • Craving
  • Medication compliance
  • Addiction severity
  • Psychiatric interview
  • Sex-risk behavior

Secondary Outcome Measures:
  • Depression
  • Quality of Life

Estimated Enrollment:   50

  Eligibility
Ages Eligible for Study:   18 Years to 65 Years
Genders Eligible for Study:   Male
Accepts Healthy Volunteers:   No

Criteria

Inclusion Criteria:

  1. HIV-seropositive, GBM receiving medical treatment for HIV for at least 30 days prior to signing informed consent at the UCLA CARE clinic, aged 18-65
  2. Willing to give informed consent and comply with study procedures;
  3. Willing to provide consent to contact treating physicians and pharmacies to assess adherence to HIV medications;
  4. Diagnosed with current methamphetamine abuse as determined by MINI; and
  5. Interested in seeking treatment for their methamphetamine abuse and in participating in this research project.

Exclusion Criteria:

  1. Unwilling to give, or withdrawal of, informed consent;
  2. Inability to understand nature of study;
  3. A psychiatric condition that, in the principal investigator's judgment, warrants additional intervention to ensure participant safety (e.g., meets DSM-IV-TR criteria for current bipolar disorder or a psychotic disorder);
  4. Current suicidal ideation or suicide attempt within the past 3 months; and
  5. Concurrent dependence on opiates, alcohol, or benzodiazepines as determined by MINI.
  6. Total lack of any type of healthcare coverage. These potential participants will be given low-fee treatment referrals.
  Contacts and Locations

Please refer to this study by its ClinicalTrials.gov identifier: NCT00249678

Locations
United States, California
UCLA CARE Clinic     Not yet recruiting
      Los Angeles, California, United States, 90035
      Contact: Ardis Moe     310-557-2273        
UCLA Medical Center     Not yet recruiting
      Los Angeles, California, United States, 90024
      Contact: Ardis Moe     310-557-2273        
UCLA, Integrated Substance Abuse Programs     Not yet recruiting
      Los Angeles, California, United States, 90024
      Contact: James Peck, Other     310-312-0500     jpeck@mednet.ucla.edu    

Sponsors and Collaborators
National Institute on Drug Abuse (NIDA)
University of California, Los Angeles

Investigators
Principal Investigator:     James Peck, Other     University of California, Los Angeles    
  More Information

Study ID Numbers:   NIDA-18075-1, R21-18075-1
First Received:   November 3, 2005
Last Updated:   November 3, 2005
ClinicalTrials.gov Identifier:   NCT00249678
Health Authority:   United States: Federal Government/HHS/NIH/NIDA

Study placed in the following topic categories:
Methamphetamine
Dopamine
HIV Infections
Acquired Immunodeficiency Syndrome

Additional relevant MeSH terms:
Dopamine Uptake Inhibitors
Neurotransmitter Uptake Inhibitors
Neurotransmitter Agents
Molecular Mechanisms of Pharmacological Action
Adrenergic Agents
Sympathomimetics
Adrenergic Uptake Inhibitors
Physiological Effects of Drugs
Central Nervous System Stimulants
Pharmacologic Actions
Autonomic Agents
Therapeutic Uses
Dopamine Agents
Peripheral Nervous System Agents
Central Nervous System Agents

ClinicalTrials.gov processed this record on September 05, 2008




Links to all studies - primarily for crawlers